Table 4.
Summary of common adverse events occuring in over 30% of patients with advanced hepatocellular carcinoma treated with GC33, a humanized antibody against glypican-3 (n = 13)
| Adverse events | 5 mg/kg n = 4 | 10 mg/kg n = 3 | 20 mg/kg n = 6 | Total no. of patients n (%) |
|---|---|---|---|---|
| Any adverse events | 4 | 3 | 6 | 13 (100) |
| Lymphocyte count decreased | 4 | 3 | 3 | 10 (77) |
| Natural killer cell count decreased | 2 | 3 | 5 | 10 (77) |
| C-reactive protein increased | 3 | 2 | 4 | 9 (69) |
| Pyrexia | 2 | 2 | 4 | 8 (62) |
| Aspartate aminotransferase increased | 1 | 2 | 3 | 6 (46) |
| Blood alkaline phosphatase increased | 1 | 1 | 4 | 6 (46) |
| Nausea | 2 | 0 | 4 | 6 (46) |
| Cancer pain | 1 | 2 | 3 | 6 (46) |
| Alanine aminotransferase increased | 1 | 2 | 2 | 5 (38) |
| Blood lactate dehydrogenase increased | 1 | 3 | 1 | 5 (38) |
| Blood albumin decreased | 1 | 0 | 3 | 4 (31) |
| Blood pressure increased | 1 | 1 | 2 | 4 (31) |
| Fatigue | 0 | 3 | 1 | 4 (31) |
| Decreased appetite | 1 | 0 | 3 | 4 (31) |